Search results
Marvelon: Desogestrel - ethinyl estradiol is an estrogen and progestin combination pill used for the prevention of pregnancy. It works by preventing ovulation (the release of an egg from an ovary) and causing changes in the mucus of the cervix that make it difficult for sperm to penetrate and for an egg to implant.
View Marvelon overdosage for action to be taken in the event of an overdose. Administration May be taken with or without food: Take at the same time each day.
These hormones prevent an egg being released from your ovaries so you can’t get pregnant. Marvelon also makes the fluid (mucus) in your cervix thicker which makes it more difficult for sperm to enter the womb. Marvelon is a 21-day pill – you take one each day for 21 days, followed by 7 days when you take no pills.
Because of the small amounts of hormones, MARVELON is considered a low-dose oral contraceptive. As all tablets in the pack combine the same hormones in the same dose, it is considered a monophasic combined oral contraceptive. MARVELON is used to prevent pregnancy.
Dosage/Direction for Use. 1 tab daily for 21 consecutive days. Each subsequent pack is starting after a 7-day placebo interval, during which time a w/drawal bleed usually occurs. Starts on day 2-3 after the last tab & may not have finished before the next pack is started.
MARVELON is a birth control pill. It is considered to be a combination oral contraceptive. This is because it contains two female sex hormones: desogestrel and ethinyl estradiol. MARVELON has been shown to be effective in preventing pregnancy when taken as prescribed by your healthcare professional.
When all 21 white pills are done, take one (1) green pill per day for 7 days. Overdose: If too many birth control pills are taken at one time, nausea, vomiting, breast tenderness, dizziness, abdominal pain, fatigue, drowsiness and vaginal bleeding in women are possible.
Stop taking Marvelon Tablet and tell your doctor if you experience unexplained swelling and discomfort in your extremities, shortness of breath, chest pain, severe headache, or vision problems. These may be signs of a venous blood clot.
The decision to prescribe Marvelon should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Marvelon compares with other CHCs (see sections 4.3 and 4.4).
MARVELON® (desogestrel and ethinyl estradiol tablets, USP) Page 8 of 57 Several epidemiological studies indicate that third generation oral contraceptives, including those containing desogestrel, are associated with a higher risk of venous thromboembolism than
